Background {#section5-1758835920942378}
==========

Lung cancer is the leading cause of cancer-related death.^[@bibr1-1758835920942378]^ In particular, small cell lung cancer (SCLC) represents 15% of all cases while large cell neuroendocrine carcinoma (LCNEC) accounts for 5%. Lung neuroendocrine carcinomas (NECs) represent poorly differentiated or high-grade lung neuroendocrine neoplasms (NENs), comprising SCLC and LCNEC in accordance with the 2015 World Health Organization (WHO) lung NEN classification.^[@bibr2-1758835920942378]^ Typical and atypical carcinoids are two further categories of this classification, representing well differentiated or low-/intermediate-grade forms. SCLC and LCNEC are NECs characterized by poor survival rates. Furthermore, the American Joint Committee on Cancer Tumor-Node-Metastasis (TNM) classification and staging system has proved to be predictive of overall survival (OS) and a number of clinical indicators such as smoking habit, gender, age and performance status seemed to be associated with prognosis.^[@bibr3-1758835920942378]^ Systemic inflammation plays an important role in tumor promotion and progression. Therefore, it is not surprising that different markers of systemic inflammation have been related to poor outcome in multiple solid neoplasms, including NEC.^[@bibr4-1758835920942378]^ Recently, a variety of novel parameters have emerged as independent prognostic factors with an interesting role in clinical practice such as advanced lung cancer inflammation index (ALI), neutrophil--lymphocyte ratio (NLR), and serum lactate dehydrogenase (LDH). The prognostic significance of ALI, which is calculated by multiplying body mass index (BMI; kg/m^2^) by the serum albumin/NLR, has been recently described in a study that showed how lower ALI value (\<19.5) was associated with poor prognosis in SCLC.^[@bibr5-1758835920942378]^ Zhang *et al.* in a recent work described the prognostic role of serum LDH, describing elevated values during cell malignant transformation, angiogenesis and hypoxia.^[@bibr6-1758835920942378]^ High levels of LDH were associated with worse prognosis, although LDH levels alone cannot have an independent prognostic significance if not associated with other strong clinical indicators such as the extent of disease, age, NLR or platelets count.^[@bibr6-1758835920942378]^ The prognostic significance of NLR has been evaluated in several studies. Specifically, it has been demonstrated that high preoperative peripheral blood NLR was associated with poor postoperative outcomes.^[@bibr7-1758835920942378]^ The advent of immune checkpoint inhibitors (ICIs) in the SCLC scenario raises the need for prognostic indicators to guide treatment strategies. For this reason, our study aimed to evaluate the prognostic significance of systemic inflammatory biomarkers in patients affected by lung NEC, focusing on NLR, LDH, and ALI. In addition, we tried to stratify our population into three prognostic groups using an innovative immune prognostic score in advanced lung NECs, the Lung Immune Prognostic Index (LIPI).

Methods {#section6-1758835920942378}
=======

Patients {#section7-1758835920942378}
--------

We conducted a retrospective analysis using peripheral blood samples of consecutive patients (aged ⩾18 years) with cytological or histological diagnosis of SCLC and LCNEC (stage IIIB--C/IV (according to version 8 of the International Association for the Study of Lung Cancer TNM Staging System). Clinical characteristics, hematologic tests and outcome data were retrospectively collected and included into an anonymized database. We excluded patients with diagnosis of well-differentiated neuroendocrine tumor, and patients who did not undergo blood sample collection at diagnosis or who have not received chemotherapy treatment for their disease. Patients with a diagnosis of cancer in the last 5 years before diagnosis were excluded. We also excluded patients who were diagnosed with active systemic inflammatory or chronic disease (Crohn's disease, ulcerative colitis, irritable bowel syndrome, thyroiditis, type 1 and 2 diabetes mellitus, other autoimmune diseases). The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines on Good Clinical Practice. The trial protocol was previously approved by the Independent Ethic Committee at University of Palermo (approval number: 0003/2020).

Study design and treatment {#section8-1758835920942378}
--------------------------

Patients were referred to two Italian cancer centers: University of Chieti and University of Palermo, from January 2002 to January 2018. All patients included in our analysis were newly diagnosed with advanced disease and received platinum-based chemotherapy as first-line regimen. The first-line chemotherapy sensitivity was categorized as chemotherapy-free interval (CFI) \>90 days.^[@bibr8-1758835920942378]^ The NLR was calculated as the ratio between the absolute count of neutrophils (ANC) and the absolute count of lymphocytes. Since no validated cut-off value has been reported, NLR was calculated according to the Youden index of the receiver operating characteristic (ROC) curve. The value of ALI was computed as BMI × serum albumin/NLR. The ALI, platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) and LDH cut-offs were obtained using the median value. The derived (d) NLR was calculated as \[ANC/(white blood cell concentration (WBC) − ANC)\]. The LIPI score was developed on the basis of dNLR greater than 3 and LDH greater than 600 U/L, stratifying our lung NEC population into three prognostic groups: good, intermediate and poor.^[@bibr9-1758835920942378]^ We categorized advanced lung NEC in two different groups, limited-stage SCLC or extensive stage SCLC, according to the modified version of the Veterans Administration Lung Cancer Study Group (VALSG) staging system that is usually applied to SCLC.^[@bibr10-1758835920942378]^ The comorbidity assessment at baseline was performed using the Charlson comorbidity index (CCI), using the median value as cut-off. Radiological evaluation of efficacy was performed by computed tomography scan every 3 months, thereafter until disease progression and treatment responses were computed according to the response evaluation criteria in solid tumors (RECIST) version 1.1.

Statistical analysis {#section9-1758835920942378}
--------------------

The ALI, PLR, LMR and LDH raw values were calculated from blood tests obtained from each patient at the same time points. Their median values were computed as the 50th percentile. Categorical variables were compared using χ^2^ test or Fisher's exact test. The best response after first line chemotherapy was categorized as complete response (CR), partial response (PR), stable disease (SD), and progression disease, according to RECIST version 1.1. OS was defined as time from diagnosis or primary intervention to last follow-up or death from any cause. The survival curves were estimated using the Kaplan--Meier method, providing median and *p* values, with the use of the log-rank test for comparisons. Univariate and multivariate analysis for the most significant variables were performed using a logistic regression model. All analyses were considered as statistically significant with a *p* value ⩽0.05. Statistical analyses were performed using the SPSS Statistics software (IBM SPSS Statistics for Windows, version 22.0. IBM Corp., Armonk, NY, USA).

Results {#section10-1758835920942378}
=======

We screened and included in our study a total of 120 patients. Of them, 110 (92%) were SCLC and 10 (8%) LCNEC. Patients' baseline characteristics are shown in [Table 1](#table1-1758835920942378){ref-type="table"}. In our population, males were prevalent (*n* = 101, 84%) and the median age was 65 years (range 39--85). Further, the majority of patients presented with an eastern cooperative oncology group performance status (ECOG PS) score of 0--1 (78%) rather than 2 (6%). Mean BMI was 26 kg/m^2^ and 53% of the patients were overweight or obese at diagnosis, according to WHO BMI classification. Data on cigarette smoking was available in only 48% of our cohort with most of them being current smokers (96%). As the onset of metastasis is very common in lung NEC disease, the CCI score is usually \>6. In fact, in line with previous reports in lung cancer, the mean CCI score was 8 in our study.^[@bibr11-1758835920942378],[@bibr12-1758835920942378]^ Most patients had advanced disease according to the VALSG staging system (58%). Among them, 44% of cases had multi-organ metastatic disease and most common sites of metastasis were liver, bone, and distant lymph nodes. In particular, brain metastases were present in 19 cases (16%). The pre-treatment serum neuron-specific enolase (NSE) level was measured in 63 patients (53%), with an average value of 69 ng/mL. The appropriate cutoff value for the NLR identified by ROC analyses was 1.93, with a sensitivity and specificity for predicting survival of 83% and 46%, respectively. The NLR value was measured before and after first-line chemotherapy and an increased NLR (delta NLR \>1) was found in 25 (21%) patients whereas a reduced NLR was found in 37 (31%). All patients had undergone platinum-based chemotherapy. Interestingly, 65% had shown a CR, PR, or SD as disease control after first-line treatment, and 29% had a first-line chemotherapy sensitive tumor according to the pre-specified CFI. Median OS was 12 months. In particular, OS for SCLC and LCNEC was 11 months and 14 months, respectively.

###### 

Characteristics of study population.

![](10.1177_1758835920942378-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                      Category                  All cases\   HR         95% CI\      *p*-value      HR         95% CI\          *p*-value
                                                                          No. (%)                 Univariate                             Multivariate     
  --------------------------------------------- ------------------------- ------------ ---------- ------------ -------------- ---------- ---------------- ------------
  **Histotype**                                 **SCLC**                  110 (92)     1 (ref.)                                                           

                                                **LCNEC**                 10 (8)       1.14       0.54--2.38   0.7                                        

  **Gender**                                    **Male**                  101 (84)     1                                                                  

                                                **Female**                19 (16)      0.88       0.52--1.47   0.62                                       

  **Age, years**                                **\< 65**                 58 (48)      1                                                                  

                                                **⩾65**                   62 (52)      1.9        1.21--2.8    **0.0019**                                 

  **BMI**                                       **Normal weight**\        51 (43)\     1\         0.56--1.35   0.50                                       
                                                **Overweight or obese**   64 (53)      0.87                                                               

  **ECOG PS**                                   **0**                     44 (37)      1          1.1--15.8    1              1          1                **4**

                                                **1**                     49 (41)      2.5        0.66--9.66   0.01           3.57       **1.05--12.5**   **0.04**

                                                **2**                     7 (6)        4.16       1.1--16.6    **0.0004**     4.34       **1.20--16.6**   **0.0025**

  **Charlson score**                            **\<8**\                  42 (35)\     1\         1.40--3.40   **0.0003**                                 
                                                ⩾8                        59 (49)      2.2                                                                

  **VALGS stage at diagnosis**                  **LD**\                   31 (26)\     1\         1.02--2.54   **0.04**                                   
                                                ED                        70 (58)      1.6                                                                

  **Multi-organ metastases, only metastatic**   **No**                    39 (56)      1                                                                  

                                                **Yes**                   31 (44)      1.72       0.99--3.0    **0.03**                                   

  **Brain metastases**                          **No**\                   81 (67)\     1\         0.64--2.11   0.57                                       
                                                Yes                       19 (16)      1.17                                                               

  **NLR**                                       **\<1.93**                23 (19)      1                                                                  

                                                **⩾1.93**                 90 (75)      2.6        1.68--4.05   **0.0002**                                 

  **ΔNLR**                                      **⩽1**                    37 (31)      1                                                                  

                                                **\>1**                   25 (21)      1.18       0.66--2.13   0.50                                       

  **LMR**                                       **\<2.82**                54 (45)      1                                                                  

                                                **⩾2.82**                 55 (46)      0.79       0.5--1.22    0.26                                       

  **PLR**                                       **\<146**\                57 (47)\     1\         0.79--1.88   0.34                                       
                                                ⩾146                      56 (47)      1.22                                                               

  **LDH, U/L**                                  **\<600**                 41 (34)      1                                      1                           

                                                **⩾600**                  38 (32)      1.69       1.01--2.81   **0.03**       **6.6**    **1.31--33.3**   **0.022**

  **Albumin, g/dL**                             **\<3.9**                 33 (28)      1                                                                  

                                                **⩾3.9**                  46 (38)      0.86       0.51--1.46   0.57                                       

  **Serum sodium, mmol/L**                      **\<130**                 5 (4)        1                                                                  

                                                **⩾130**                  94 (79)      1.82       0.48--6.87   0.22                                       

  **CRP, mg/dL**                                **\<1**                   14 (12)      1                                                                  

                                                **⩾1**                    12 (10)      1.84       0.74--4.6    0.14                                       

  **NSE, ng/mL**                                **\<20**                  19 (16)      1                                                                  

                                                **⩾20**                   44 (37)      1.14       0.60--2.16   0.69                                       

  **ALI, BMI\*ALB/NLR**                         **\<34**                  38 (32)      1                                                                  

                                                **⩾34**                   37 (31)      0.49       0.28--0.86   **0.0065**                                 

  **6-month disease control, CR+PR+SD**         **No**                    31 (34)      1                                      1                           

                                                **Yes**                   58 (65)      0.25       0.11--0.60   **\<0.0001**   **0.15**   **0.04--0.55**   **0.004**

  **First line sensitivity**                    **No**                    50 (42)      1                                                                  

                                                **Yes**                   35 (29)      0.39       0.24--0.63   **\<0.0001**                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Univariate and multivariate analysis; SCLC; LCNEC; body mass index was categorized as underweight (\<18.5 kg/m^2^), normal (18.5--24.9 kg/m^2^), overweight (⩾25.0 kg/m^2^). First line sensitivity was categorized as chemotherapy free-interval \>90 days.

ALB, albumin; ALI, advanced lung cancer inflammation index; BMI, body mass index; CI, confidence interval; CR, complete response; CRP, C-reactive protein; ΔNLR: pre-treatment to post-treatment NLR changes; ED, extensive disease; HR, hazard ratio; LCNEC; large cell neuroendocrine carcinoma; LD, limited disease; LDH, lactate dehydrogenase; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; NSE, serum neuron specific enolase; PLR, platelet-to-lymphocyte ratio; PR, partial response; ECOG PS, Eastern Cooperative Oncology Group performance status; ref., reference; SCLC, small cell lung cancer; SD, stable disease; VALGS, Veterans Administration Lung Study Group.

As regards the univariate analysis, a positive prognostic value for OS was found in patients with pre-treatment NLR \<1.93 (log-rank test *p* = 0.0002), LDH \<600 U/L (*p* = 0.03) and ALI ⩾34 (*p* = 0.0065) ([Figures 1](#fig1-1758835920942378){ref-type="fig"}[](#fig2-1758835920942378){ref-type="fig"}--[3](#fig3-1758835920942378){ref-type="fig"} and [Table 1](#table1-1758835920942378){ref-type="table"}). Moreover, other clinical meaningful parameters such as age at diagnosis \<65 years (*p* = 0.0019), lower ECOG PS (1 *versus* 0 *p* = 0.02; 2 *versus* 0 *p* = 0.0004), CCI \<8 (*p* = 0.0003), limited disease (*p* = 0,04), one site of distant metastasis (*p* = 0.03), disease control after first-line chemotherapy (CR+PR+SD; *p* ⩽ 0.0001) and first line sensitivity (*p* ⩽ 0.0001) were significantly associated with a better survival. At the multivariate analysis, ECOG PS, LDH levels and response after first-line chemotherapy maintained their significance for OS and should be considered as independent prognostic factors in our series ([Table 1](#table1-1758835920942378){ref-type="table"}).

![Kaplan--Meier survival curve for overall survival (OS) according to neutrophil--lymphocyte ratio (NLR) values.](10.1177_1758835920942378-fig1){#fig1-1758835920942378}

![Kaplan--Meier survival curve for overall survival (OS) according to lactate dehydrogenase (LDH) values.](10.1177_1758835920942378-fig2){#fig2-1758835920942378}

![Kaplan--Meier survival curve for overall survival (OS) according to lung cancer inflammation index (ALI) values.](10.1177_1758835920942378-fig3){#fig3-1758835920942378}

Forty-one (34%) patients without baseline LDH or dNLR were excluded from the LIPI analysis. Among the 78 evaluable patients, 34 (43%) had good LIPI score, 35 (45%) had intermediate LIPI score, and nine (11%) had poor LIPI score. About LIPI and OS, our analysis showed OS values of 15 months *versus* 11 months *versus* 9 months according to good, intermediate, and poor LIPI groups, respectively, showing a trend toward statistical significance (*p* = 0.091) ([Figure 4](#fig4-1758835920942378){ref-type="fig"}). A significantly increased probability of tumor progression was observed in those patients with higher NLR before treatment, while patients with NLR \<1.93 showed a lower probability of tumor progression (*p* = 0.045, χ^2^ test) ([Figure 5](#fig5-1758835920942378){ref-type="fig"}).

![Kaplan--Meier survival curve for overall survival (OS) according to Lung Immune Prognostic Index (LIPI) values.](10.1177_1758835920942378-fig4){#fig4-1758835920942378}

![Number of patients who reach disease control stratified by neutrophil--lymphocyte ratio (NLR). In the χ^2^ test patients were divided into two groups (NLR ⩽1.93 and NLR \>1.93). Patients in the NLR \>1.93 group showed a significantly higher progressive disease rate than patients in the NLR ⩽1.93 group.](10.1177_1758835920942378-fig5){#fig5-1758835920942378}

Discussion {#section11-1758835920942378}
==========

Lung NECs are considered as rare tumors characterized by lack of treatment advances over the last 30 years. Over recent decades, ICIs revolutionized cancer care of several aggressive solid tumors, including non-small cell lung cancer, melanoma and Merkel-cell carcinoma. The strong association with smoking habit and high mutational rate suggested a potential immunogenicity of lung NEC and provided the rationale for adding ICIs to chemotherapy to enhance antitumor immunity and improve outcomes.^[@bibr13-1758835920942378]^

The role of ICIs is currently under investigation in LCNEC, whereas recent studies demonstrated encouraging data from SCLC patients.

Due to the rarity of lung NECs, identification of independent prognostic and predictive factors is an important unmet clinical need. Gender, extent of disease, ECOG PS, hemoglobin, LDH, NSE and chemotherapy disease control are well-recognized prognostic factors for SCLC and LCNEC.^[@bibr14-1758835920942378][@bibr15-1758835920942378][@bibr16-1758835920942378][@bibr17-1758835920942378][@bibr18-1758835920942378][@bibr19-1758835920942378]--[@bibr20-1758835920942378]^

Despite that emerging evidences have confirmed an important role of inflammatory response in tumor progression, there is no robust evidence regarding systemic inflammatory biomarkers in this setting.

Moreover, since different trials showed that improvements from ICIs are limited to a small subset of patients,^[@bibr21-1758835920942378]^ further identification of predictive biomarkers is crucial in order to improve a better selection of patients.

Besides the well-known inflammatory biomarkers, including LDH and hypoalbuminemia, novel parameters have been investigated, such as NLR, ALI and LIPI score, all of which are associated with survival in cancer.

As novel biomarkers, NLR and dNLR measure the inflammation/immunity ratio in various solid tumors. The dNLR differs from NLR because it includes monocytes and other granulocyte subpopulations that could contribute to the process.^[@bibr9-1758835920942378]^ Elevated NLR values are related to neutrophilia and lymphocytopenia.

Neutrophils seem to dominate the lung cancer landscape, as showed by Kargl *et al.*, being responsible for the ICI resistance.^[@bibr22-1758835920942378]^ The tumor microenvironment, rich in neutrophils, can be artificially manipulated and stimulated in order to develop a pro-inflammatory status related to tumor progression.^[@bibr23-1758835920942378]^ This "negative inflammation", responsible for ICI resistance, may be reflected by the aforementioned inflammatory biomarkers (NLR, LIPI).

The significance of these systemic inflammatory markers could be explained by the role of neutrophils in promoting inflammation and consequently an adequate environment for tumor growth.^[@bibr24-1758835920942378]^ Neutrophils promote remodeling of the extracellular matrix and tumor progression by activating a large variety of inflammatory markers such as vascular endothelial growth factor and anti-apoptotic factors such as nuclear factor kappa-light-chain-enhancer of activated B cells.^[@bibr25-1758835920942378]^ On the contrary, lymphocyte count reflects the immune system activation and the consequent inhibiting effect on tumor proliferation and migration.^[@bibr24-1758835920942378]^ It is well known that inflammation reduces albumin levels irrespective of the patient's nutritional status,^[@bibr26-1758835920942378]^ and low albumin has also been recognized as a negative prognostic factor in several diseases, especially solid tumors.^[@bibr27-1758835920942378]^ In addition, the relationship between immune system and energetic metabolism, in both obese and cachectic patients, and its impact on tumor progression are active fields of investigation.^[@bibr28-1758835920942378]^ Accordingly, previous studies investigated ALI score, based on albumin level and BMI together with NLR, to validate the degree of systemic inflammation at diagnosis.^[@bibr5-1758835920942378],[@bibr29-1758835920942378]^ As mentioned previously, LIPI score, a combined score including dNLR and LDH, has proved to be useful for stratifying those patients treated with ICIs in prognostic groups,^[@bibr30-1758835920942378]^ raising the hypothesis that it might be useful as a predictive tool. Our aim was to evaluate the role of combined routine blood parameters, such as systemic inflammatory biomarkers, in order to investigate the effect of inflammatory status on lung NEC outcomes. Results of this article confirmed recent reports about the prognostic role of NLR and other factors such as LIPI also in patients who underwent conventional chemotherapy.^[@bibr31-1758835920942378],[@bibr32-1758835920942378]^ After the introduction of ICIs in SCLC, it should be interesting to evaluate the role of steroids (above all ⩾10 mg of prednisone or equivalent) because of its role as neutrophilia and lymphopenia factor and its relationship with LIPI and prognosis worsening, as suggested by studies on non-small cell lung cancer.^[@bibr33-1758835920942378]^

LDH is an important and widely studied inflammatory biomarker, which acquired a prognostic and predictive role in melanoma patients treated with Program Death 1 inhibitors. LDH has also been studied in SCLC with its role being still controversial, even in the definition of cut-off values. Nonetheless, a recent meta-analysis showed that a high LDH value was associated with poor prognosis.^[@bibr30-1758835920942378]^

Furthermore, our results showed a favorable survival in patients with pre-treatment NLR \<1.93, LDH \<600 U/L and ALI ⩾34. Moreover, analysis of other clinical parameters showed that age at diagnosis \<65 years, lower ECOG PS, CCI \<8, limited disease, low tumor burden, disease control after first-line chemotherapy and first line sensitivity were significantly associated with a better survival. Only ECOG PS, LDH levels and response after first-line chemotherapy maintained their significance for OS at the multivariate analysis. Stratification through LIPI score allowed us to identify three prognostic groups, categorized as good, intermediate and poor, with a trend toward statistical significance.

Finally, our results showed that patients with NLR \>1.93 reflect a higher probability of tumor progression, while patients with NLR values lower than 1.93 seemed to have a decreased probability of disease progression ([Figure 5](#fig5-1758835920942378){ref-type="fig"}). The association between high level of NLR and poor prognosis is supported by strong evidences suggesting that systemic inflammatory response influences tumor progression.

Conclusion {#section12-1758835920942378}
==========

With our retrospective analysis, we provided evidence that levels of NLR, LDH and ALI evaluated at diagnosis showed a significant prognostic role in lung NEC, while LIPI stratified patients into three prognostic groups: good, intermediate and poor. Limitations include the retrospective design and the low number of centers involved, which could affect the study for selection bias. However, to reduce the risk of bias, we have recruited consecutive patients. The prognostic role of LIPI did not achieve the statistical significance probably because of the lack of power in our sample size and data on LDH. Multivariate analysis contributes to adjust our results for clinical characteristics. Therefore, a future multicenter study is needed for a prospective validation of our results. To the best of our knowledge, this is the first attempt to evaluate the prognostic role of LIPI in advanced lung NEC. Our results are consistent with previous studies focused on lung NEC, as summarized in [Table 2](#table2-1758835920942378){ref-type="table"},^[@bibr6-1758835920942378],[@bibr7-1758835920942378],[@bibr9-1758835920942378],[@bibr29-1758835920942378],[@bibr34-1758835920942378][@bibr35-1758835920942378]--[@bibr36-1758835920942378]^ and could facilitate the understanding of survival differences in advanced lung NEC patients in the clinical setting, suggesting a role of systemic inflammatory biomarkers in the management of advanced lung NEC patients.

###### 

Summary of published data for routine inflammatory biomarkers.

![](10.1177_1758835920942378-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                            Tumor   No. of patients   Study           Marker     Outcomes          Significance
  ---------------------------------------------------- ------- ----------------- --------------- ---------- ----------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Eun Young Kim *et al.*^[@bibr19-1758835920942378]^   SCLC    186               Retrospective   ALI        Low ALI\          **Univariate**\
                                                                                                            Good prognosis    HR 2.10\
                                                                                                                              95% CI 1.50 ± 2.94\
                                                                                                                              *p* value \<0.001\
                                                                                                                              **Multivariate**\
                                                                                                                              HR 1.67\
                                                                                                                              95% CI 1.17 ± 2.37\
                                                                                                                              *p* value\
                                                                                                                              0.004

  Masayuki Okui *et al.*^[@bibr7-1758835920942378]^    LCNEC   1890              Retrospective   NLR        High NLR\         **Multivariate**\
                                                                                                            Poor prognosis    HR 8.559\
                                                                                                                              95% CI 1.260--58.139\
                                                                                                                              *p* value 0.028

  Laura Mezquita *et al.*^[@bibr8-1758835920942378]^   NSCLC   466               Retrospective   LIPI       High LIPI\        3 months \[95% CI, 1 month to not reached (NR)\] *versus* 10 months (95% CI, 8 months to NR) *versus 3*4 months (95% CI, 17 months to NR) for the poor, intermediate, and good\
                                                                                                            Poor prognosis    LIPI groups, respectively\
                                                                                                                              (*p* \< 0.001)

  Xiuxiu Zhang *et al.*^[@bibr6-1758835920942378]^     SCLC    4785              Meta-analysis   LDH        High LDH\         HR 1.45\
                                                                                                            Poor prognosis    95% CI 1.27--1.66

  Xuan Hong *et al.*^[@bibr21-1758835920942378]^       SCLC    919               Retrospective   NLR        High NLR\         HR 0.908\
                                                                                                            Poor prognosis    95% CI 0.721--1.144\
                                                                                                                              *p* value 0.413

  Min Deng *et al.*^[@bibr22-1758835920942378]^        SCLC    320               Retrospective   NLR, LDH   High NLR\         **NLR**\
                                                                                                            Poor prognosis\   HR 1.35\
                                                                                                            High LDH\         95% CI 1.02--1.79\
                                                                                                            Poor prognosis    *p* value 0.039\
                                                                                                                              LDH\
                                                                                                                              HR 1.46\
                                                                                                                              95% CI 1.10--1.96\
                                                                                                                              *p* value 0.010

  Dan Liu *et al.*^[@bibr24-1758835920942378]^         SCLC    139               Retrospective   NLR        High NLR\         **Univariate analysis**\
                                                                                                            Poor prognosis    NLR \>4.55 *versus* ⩽4.55\
                                                                                                                              HR 3.309\
                                                                                                                              95% CI 2.088--5.244\
                                                                                                                              *p* value 0.000\
                                                                                                                              **Multivariate analysis**\
                                                                                                                              HR 2.093\
                                                                                                                              95% CI 1.079--4.063\
                                                                                                                              *p* value 0.029

  Xin Wang *et al.*^[@bibr23-1758835920942378]^        SCLC    153               Retrospective   NLR        High NLR\         HR 1.724\
                                                                                                            Poor prognosis    95% CI 1.116--2.663\
                                                                                                                              *p* value 0.014
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALI, advanced lung cancer inflammation index; CI, confidence interval; HR, hazard ratio; LCNEC, large cell neuroendocrine carcinoma; LDH, lactate dehydrogenase; LIPI, lung inflammation prognostic index; NLR, neutrophil-to-lymphocyte ratio; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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